Mezagitamab by Takeda Pharmaceutical for Multiple Myeloma (Kahler Disease): Likelihood of Approval

Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mezagitamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mezagitamab overview

Mezagitamab (TAK-079) is under development for the treatment of primary immune thrombocytopenia, myasthenia gravis, primary IgA nephropathy, systemic lupus erythematosus, relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma. The drug candidate is administered intravenously or subcutaneously. It is an anti-CD38 human IgG1 monoclonal antibody. It was under development for the treatment of rheumatoid arthritis.

Takeda Pharmaceutical overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

For a complete picture of Mezagitamab’s drug-specific PTSR and LoA scores, buy the report here.